Tatva Chintan Pharma Chem: SEBI Takeover Disclosure Filed

M&A / JV 24 Jun 2026 · Announced· ✓ Verified

Tatva Chintan Pharma Chem Limited, a specialty pharmaceutical chemical manufacturer listed on NSE, has submitted a mandatory disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires disclosure when a person acquires shares or voting rights that result in substantial shareholding (typically 25% or more). The filing was submitted to NSE and archived on 22 June 2026. The company is a manufacturer of specialty chemicals for pharmaceuticals and agrochemicals, with operations in Gujarat. Further details regarding the acquirer identity, acquisition size, and consideration structure depend on the full Form of…

Why it mattersA Regulation 31(4) disclosure signals that an acquirer has crossed a 25% or material shareholding threshold and must now make an open offer or seek exemption; partners should track the substantive acquisition notice and review exemption claims under Regulation 10 if applicable.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals